Atlas Trials

RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure

Clinical trial NCT06663007 · RECRUITING

Trial details

NCT number
NCT06663007
Sponsor
Tianjin Medical University Second Hospital
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Prostate CancerCDK12 Gene Mutation
Start date
2024-09-24
Primary completion
2027-05-31
Enrollment
72

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.